Point72 DIFC Ltd Takes $32,000 Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Point72 DIFC Ltd purchased a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 6,010 shares of the company’s stock, valued at approximately $32,000.

A number of other large investors have also recently modified their holdings of CLPT. Marshall Wace LLP lifted its position in ClearPoint Neuro by 202.2% in the 2nd quarter. Marshall Wace LLP now owns 58,260 shares of the company’s stock worth $314,000 after buying an additional 38,984 shares during the last quarter. XTX Topco Ltd lifted its position in ClearPoint Neuro by 11.6% in the 2nd quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock worth $70,000 after buying an additional 1,353 shares during the last quarter. Renaissance Technologies LLC lifted its position in ClearPoint Neuro by 562.6% in the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock worth $915,000 after buying an additional 144,088 shares during the last quarter. Rinkey Investments bought a new stake in ClearPoint Neuro in the 2nd quarter worth approximately $307,000. Finally, Legato Capital Management LLC lifted its position in ClearPoint Neuro by 21.6% in the 2nd quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock worth $857,000 after buying an additional 28,227 shares during the last quarter. Institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

Shares of CLPT stock opened at $11.19 on Monday. ClearPoint Neuro, Inc. has a fifty-two week low of $4.05 and a fifty-two week high of $13.47. The company has a market capitalization of $306.83 million, a P/E ratio of -13.32 and a beta of 1.12. The stock has a 50 day moving average price of $10.44 and a two-hundred day moving average price of $7.59.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. The firm had revenue of $7.86 million for the quarter, compared to analysts’ expectations of $7.50 million. During the same period in the previous year, the firm earned ($0.29) earnings per share. As a group, equities analysts predict that ClearPoint Neuro, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CLPT. Lake Street Capital boosted their target price on ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. B. Riley initiated coverage on ClearPoint Neuro in a research report on Thursday, July 25th. They issued a “buy” rating and a $10.00 price objective for the company.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.